ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
47 announcements with these filters
Glenmark reported 15.8% Q4 revenue growth (INR 37,706 Mn) and 27.5% FY26 growth. Strategy focuses on respiratory, oncology innovations, and U.S. injectable ramp-up following a landmark AbbVie licensing deal.
Glenmark Pharmaceuticals launched Lacosamide Injection USP in the United States. This expansion of their injectable portfolio targets a market with $15.2 million in annual sales.
Glenmark delivered strong FY26 growth, hitting gross debt-free status, yet Q4 US margins were squeezed by timing delays and fixed-cost under-absorption.
Glenmark Q4 FY26 consolidated revenue grew 15.8% YoY to ₹37,706m with 20.2% EBITDA margin. Growth driven by landmark AbbVie licensing deal and strong momentum in respiratory franchise.
Glenmark Pharmaceuticals reported FY26 consolidated revenue of ₹16,982.5 Crore, up 27.5% YoY. The company achieved a 26.9% EBITDA margin driven by key product launches and partnerships.
Glenmark Pharmaceuticals recommended a final dividend of ₹2.5 per equity share for FY2026. Shareholder approval at the upcoming general meeting is required for payment.
Glenmark Pharmaceuticals approved transferring its Nebulizer portfolio to its subsidiary for ₹223 Crore. The restructuring aims to enhance strategic focus and respiratory innovation leadership.
Glenmark Pharmaceuticals appointed Ms. Rashmi Khandelwal as Company Secretary following Mr. Harish Kuber's retirement. Ms. Khandelwal brings 17 years of corporate governance experience to the role.
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹3,771 Cr (+15.8% YoY) and net profit of ₹301.3 Cr (+6747.7% YoY) for Q4 FY26.
Glenmark Pharmaceuticals approved FY26 audited financial results and recommended a 250% dividend. The Board's approval highlights the company's annual performance and shareholder reward plans.
Glenmark USA settled US antitrust litigation with state attorneys general for ₹281.47 Crore. Payable over five years, the settlement avoids uncertainty without admitting any liability.
Glenmark's subsidiary announced ISB 2301, a first-in-class multispecific activator targeting solid tumors. Clinical studies are planned for 2027 following IND submission later this year.
Glenmark Pharmaceuticals scheduled a board meeting for May 29, 2026. Directors will approve FY26 financial results and consider recommending a dividend to shareholders.
Glenmark launched Vancomycin Hydrochloride for Injection in the U.S. market. The product targets a ₹363.84 Crore market, strengthening the company's injectable portfolio and presence.
Glenmark Pharmaceuticals Limited confirmed it is not classified as a Large Corporate as per SEBI criteria for the financial year. Consequently, the company is not required to submit incremental debt disclosures under the circular framework. The filing reports zero outstanding borrowings as of the reporting date.
Glenmark Pharmaceuticals received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg. The product targets a market with annual sales of approximately ₹544.64 Crore ($59.2 million). This approval strengthens Glenmark's women's healthcare portfolio in the U.S. market.
Glenmark Pharmaceuticals Ltd reported net profit of ₹403 Cr (+15.8% YoY) for Q3 FY26.